Pfizer offered new evidence on Wednesday in support of booster shots of its potent vaccine, reporting that the vaccine’s power wanes slightly over time but may be improved with a third dose.
July 28, 2021, 8:22 PMA student receives a second dose of the Pfizer coronavirus vaccine at the Morris Heights Heath Center in the Bronx on Tuesday, July 27, 2021.
Still, the findings raise questions about how much protection two doses will provide in the months to come. And with coronavirus cases surging again in many states, the data may influence the Biden administration’s deliberations about delivering boosters. The vaccine had a sky-high efficacy rate of about 96% against symptomatic COVID-19 for the first two months following the second dose, the study showed. But the figure declined by about 6% every two months after that, falling to 83.7% after about four to six months.“It’s not a big drop, but it is noteworthy,” Dean said. “Overall, they find that the vaccine is still performing very well, at very high efficacy.
In other words, the risk of getting sick was reduced by 95% in the group that got the vaccine, compared with the group that got the placebo. That result — the first for any COVID-19 vaccine — brought an exhilarating dose of hope to the world in December when it was riding what had been the biggest wave of the pandemic.
But within that period, efficacy did gradually drop. Between one week and two months after the second dose, the figure was 96.2%. In the period from two to four months following vaccination, efficacy fell to 90.1%. From four months after vaccination to the March cutoff, the figure was 83.7%. Results were similar for antibodies produced against the original virus and the beta variant, which was first identified in South Africa. Pfizer and BioNTech expect to publish more definitive research in the coming weeks.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Stocks making the biggest moves premarket: McDonald's, Boeing, Pfizer, Spotify and moreThese are the stocks posting the largest moves before the bell.
Leer más »
Pfizer Raises Full-Year Outlook on Covid-19 Vaccine SalesThe pharmaceutical company’s Covid-19 vaccine co-developed with BioNTech contributed $7.8 billion to Pfizer’s total sales of $18.98 billion in the latest quarter.
Leer más »
Israel Begins Pfizer Covid-19 Vaccine for At-Risk Children Under 12 as Delta Cases SurgeThe country has authorized the use of Pfizer’s Covid-19 vaccine for vulnerable children between five and 11 years old, as cases of the highly contagious Delta variant rise sharply.
Leer más »
Pfizer And Moderna To Expand Studies Of Vaccines In 5- To 11-Year-OldsAt the request of the FDA, the vaccine makers are expanding their trials with young children, seeking to better detect very rare heart issues.
Leer más »
Pfizer And Moderna To Expand Studies Of Vaccines In 5- To 11-Year-OldsAt the request of the FDA, the vaccine makers are expanding their trials with young children, seeking to better detect very rare heart issues.
Leer más »